APA

Rusnak D. W., Affleck K., Cockerill S. G., Stubberfield C., Harris R., Page M., Smith K. J., Guntrip S. B., Carter M. C., Shaw R. J., Jowett A., Stables J., Topley P., Wood E. R., Brignola P. S., Kadwell S. H., Reep B. R., Mullin R. J., Alligood K. J., Keith B. R., Crosby R. M., Murray D. M., Knight W. B., Gilmer T. M. & Lackey K. (20011018). The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. : Cancer research.

Chicago

Rusnak D W, Affleck K, Cockerill S G, Stubberfield C, Harris R, Page M, Smith K J, Guntrip S B, Carter M C, Shaw R J, Jowett A, Stables J, Topley P, Wood E R, Brignola P S, Kadwell S H, Reep B R, Mullin R J, Alligood K J, Keith B R, Crosby R M, Murray D M, Knight W B, Gilmer T M and Lackey K. 20011018. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. : Cancer research.

Harvard

Rusnak D. W., Affleck K., Cockerill S. G., Stubberfield C., Harris R., Page M., Smith K. J., Guntrip S. B., Carter M. C., Shaw R. J., Jowett A., Stables J., Topley P., Wood E. R., Brignola P. S., Kadwell S. H., Reep B. R., Mullin R. J., Alligood K. J., Keith B. R., Crosby R. M., Murray D. M., Knight W. B., Gilmer T. M. and Lackey K. (20011018). The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. : Cancer research.

MLA

Rusnak D W, Affleck K, Cockerill S G, Stubberfield C, Harris R, Page M, Smith K J, Guntrip S B, Carter M C, Shaw R J, Jowett A, Stables J, Topley P, Wood E R, Brignola P S, Kadwell S H, Reep B R, Mullin R J, Alligood K J, Keith B R, Crosby R M, Murray D M, Knight W B, Gilmer T M and Lackey K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. : Cancer research. 20011018.